<p>Wealthquest Corp 在第一季度購買了 Amedisys, Inc. (NASDAQ:AMED - 免費報告) 的新股份，根據該公司最近向證券交易委員會 (SEC) 提交的 13F 文件顯示。這家機構投資者購買了 13,516 股該健康服務提供商的股票，價值約為 1,310,000 美元。</p>
<p>其他一些對沖基金最近也調整了對 AMED 的持股。挪威銀行在第四季度購買了價值 83,061,000 美元的 Amedisys 新股份。Pentwater Capital Management LP 在第四季度將其對 Amedisys 的持股增加了 178.3%。Pentwater Capital Management LP 現在擁有 1,180,000 股該健康服務提供商的股票，價值 107,132,000 美元，此前在上個季度又收購了 756,000 股。AQR Arbitrage LLC 在第四季度將其對 Amedisys 的持股增加了 59.1%。AQR Arbitrage LLC 現在擁有 471,965 股該健康服務提供商的股票，價值 42,812,000 美元，此前在上個季度又收購了 175,311 股。多倫多道明銀行在第四季度購買了價值 15,801,000 美元的 Amedisys 新股份。最後，CIBRA Capital Ltd 在第一季度將其對 Amedisys 的持股增加了 359.7%。CIBRA Capital Ltd 現在擁有 216,775 股該健康服務提供商的股票，價值 20,080,000 美元，此前在上個季度又收購了 169,616 股。對沖基金和其他機構投資者持有該公司 94.36% 的股票。</p>
<h2>Amedisys 價格表現</h2>
<p>NASDAQ:AMED 的股票在週四開盤價為 98.69 美元。該公司的流動比率為 1.29，速動比率為 1.29，債務與股本比率為 0.27。Amedisys, Inc. 的一年低點為 82.15 美元，一年高點為 98.77 美元。該公司的 50 日簡單移動平均為 96.55 美元，200 日簡單移動平均為 94.07 美元。該公司的市值為 32.4 億美元，市盈率為 38.40，市盈增長比率為 1.33，貝塔值為 0.94。</p>
<p>Amedisys (NASDAQ:AMED - 獲取免費報告) 最近在 7 月 29 日星期二發佈了其財報。該健康服務提供商報告本季度每股收益為 1.54 美元，超出市場共識預期的 1.39 美元，超出 0.15 美元。Amedisys 的股本回報率為 13.09%，淨利潤率為 3.56%。該公司本季度的收入為 6.2186 億美元，而分析師預期為 6.1461 億美元。去年同期，該公司每股收益為 0.98 美元。與去年同期相比，該公司的收入增長了 5.2%。整體來看，賣方分析師預測 Amedisys, Inc. 本財年的每股收益將達到 4.4 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位分析師最近對 AMED 股票發佈了報告。加拿大皇家銀行在 4 月 16 日星期三重申了對 Amedisys 的 &#34;跑贏大盤&#34; 評級，並設定了 100.00 美元的目標價。華爾街 Zen 在 5 月 24 日星期六將 Amedisys 的評級從 &#34;強力買入&#34; 下調至 &#34;買入&#34;。</p>
<p><strong>閲讀我們關於 AMED 的最新研究報告</strong></p>
<h2>關於 Amedisys</h2>
<p>(免費報告)</p>
<p>Amedisys, Inc. 及其子公司在美國提供醫療服務。它通過三個部門運營：家庭健康、臨終關懷和高強度護理。家庭健康部門為患者從手術、慢性疾病或絕症中恢復提供一系列服務，並通過其專業護士預防可避免的住院再入；護理服務、專注於物理、語言和職業治療的康復治療師；以及社工和助理來協助患者。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Amedisys</li>
<li>高分紅 REIT：它們是理想的多元化方式嗎？</li>
<li>Visa 超過第三季度盈利預期，市場為何恐慌？</li>
<li>英國市場假期有哪些？如何投資和交易</li>
<li>Marvell 如何從短期目標變成突破明星</li>
<li>寶潔 NYSE: PG 在不穩定的指引後回落</li>
<li>Palo Alto Networks：全能網絡安全巨頭</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1FRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1FRA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Amedisys 嗎？</h2>
<p>在你考慮 Amedisys 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Amedisys 並不在名單上。</p>
<p>雖然 Amedisys 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

阿米斯醫療

<p>Wealthquest Corp 在第一季度收購了 Amedisys, Inc.（NASDAQ:AMED）的新股份，購買了 13,516 股，價值約為 131 萬美元，具體情況在其最近的 SEC 文件中披露。其他機構投資者也增加了對 Amedisys 的持股，其中挪威銀行和 Pentwater Capital Management 的購買尤為顯著。Amedisys 報告的季度每股收益為 1.54 美元，超出預期，收入為 6.2186 億美元，同比增長 5.2%。分析師對該股票保持樂觀，當前股價為 98.69 美元</p>

<p>Wealthquest Corp bought a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 13,516 shares of the health services provider's stock, valued at approximately $1,310,000.</p>
<div class="lb-trans"><p>Wealthquest Corp 在第一季度購買了 Amedisys, Inc. (NASDAQ:AMED - 免費報告) 的新股份，根據該公司最近向證券交易委員會 (SEC) 提交的 13F 文件顯示。這家機構投資者購買了 13,516 股該健康服務提供商的股票，價值約為 1,310,000 美元。</p>
</div><p>A number of other hedge funds also recently modified their holdings of AMED. Norges Bank purchased a new stake in shares of Amedisys in the fourth quarter valued at $83,061,000. Pentwater Capital Management LP raised its holdings in shares of Amedisys by 178.3% during the fourth quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider's stock worth $107,132,000 after acquiring an additional 756,000 shares in the last quarter. AQR Arbitrage LLC raised its holdings in shares of Amedisys by 59.1% during the fourth quarter. AQR Arbitrage LLC now owns 471,965 shares of the health services provider's stock worth $42,812,000 after acquiring an additional 175,311 shares in the last quarter. Toronto Dominion Bank purchased a new stake in shares of Amedisys during the fourth quarter worth $15,801,000. Finally, CIBRA Capital Ltd raised its holdings in shares of Amedisys by 359.7% during the first quarter. CIBRA Capital Ltd now owns 216,775 shares of the health services provider's stock worth $20,080,000 after acquiring an additional 169,616 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金最近也調整了對 AMED 的持股。挪威銀行在第四季度購買了價值 83,061,000 美元的 Amedisys 新股份。Pentwater Capital Management LP 在第四季度將其對 Amedisys 的持股增加了 178.3%。Pentwater Capital Management LP 現在擁有 1,180,000 股該健康服務提供商的股票，價值 107,132,000 美元，此前在上個季度又收購了 756,000 股。AQR Arbitrage LLC 在第四季度將其對 Amedisys 的持股增加了 59.1%。AQR Arbitrage LLC 現在擁有 471,965 股該健康服務提供商的股票，價值 42,812,000 美元，此前在上個季度又收購了 175,311 股。多倫多道明銀行在第四季度購買了價值 15,801,000 美元的 Amedisys 新股份。最後，CIBRA Capital Ltd 在第一季度將其對 Amedisys 的持股增加了 359.7%。CIBRA Capital Ltd 現在擁有 216,775 股該健康服務提供商的股票，價值 20,080,000 美元，此前在上個季度又收購了 169,616 股。對沖基金和其他機構投資者持有該公司 94.36% 的股票。</p>
</div><h2>Amedisys Price Performance</h2>
<div class="lb-trans"><h2>Amedisys 價格表現</h2>
</div><p>Shares of NASDAQ:AMED opened at $98.69 on Thursday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.27. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.77. The business has a fifty day simple moving average of $96.55 and a 200 day simple moving average of $94.07. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of 38.40, a P/E/G ratio of 1.33 and a beta of 0.94.</p>
<div class="lb-trans"><p>NASDAQ:AMED 的股票在週四開盤價為 98.69 美元。該公司的流動比率為 1.29，速動比率為 1.29，債務與股本比率為 0.27。Amedisys, Inc. 的一年低點為 82.15 美元，一年高點為 98.77 美元。該公司的 50 日簡單移動平均為 96.55 美元，200 日簡單移動平均為 94.07 美元。該公司的市值為 32.4 億美元，市盈率為 38.40，市盈增長比率為 1.33，貝塔值為 0.94。</p>
</div><p>Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.15. Amedisys had a return on equity of 13.09% and a net margin of 3.56%. The company had revenue of $621.86 million for the quarter, compared to analyst estimates of $614.61 million. During the same period last year, the company earned $0.98 earnings per share. The business's revenue was up 5.2% compared to the same quarter last year. As a group, sell-side analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Amedisys (NASDAQ:AMED - 獲取免費報告) 最近在 7 月 29 日星期二發佈了其財報。該健康服務提供商報告本季度每股收益為 1.54 美元，超出市場共識預期的 1.39 美元，超出 0.15 美元。Amedisys 的股本回報率為 13.09%，淨利潤率為 3.56%。該公司本季度的收入為 6.2186 億美元，而分析師預期為 6.1461 億美元。去年同期，該公司每股收益為 0.98 美元。與去年同期相比，該公司的收入增長了 5.2%。整體來看，賣方分析師預測 Amedisys, Inc. 本財年的每股收益將達到 4.4 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several analysts recently issued reports on AMED shares. Royal Bank Of Canada reiterated an &#34;outperform&#34; rating and set a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Wall Street Zen lowered Amedisys from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, May 24th.</p>
<div class="lb-trans"><p>幾位分析師最近對 AMED 股票發佈了報告。加拿大皇家銀行在 4 月 16 日星期三重申了對 Amedisys 的 &#34;跑贏大盤&#34; 評級，並設定了 100.00 美元的目標價。華爾街 Zen 在 5 月 24 日星期六將 Amedisys 的評級從 &#34;強力買入&#34; 下調至 &#34;買入&#34;。</p>
</div><p><strong>Read Our Latest Research Report on AMED</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 AMED 的最新研究報告</strong></p>
</div><h2>About Amedisys</h2>
<div class="lb-trans"><h2>關於 Amedisys</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.</p>
<div class="lb-trans"><p>Amedisys, Inc. 及其子公司在美國提供醫療服務。它通過三個部門運營：家庭健康、臨終關懷和高強度護理。家庭健康部門為患者從手術、慢性疾病或絕症中恢復提供一系列服務，並通過其專業護士預防可避免的住院再入；護理服務、專注於物理、語言和職業治療的康復治療師；以及社工和助理來協助患者。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Amedisys</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>How Marvell Went From Short Target to Breakout Star</li>
<li>Procter &amp; Gamble NYSE: PG Pulls Back After Shaky Guidance</li>
<li>Palo Alto Networks: The All‑in‑One Cybersecurity Powerhouse</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Amedisys</li>
<li>高分紅 REIT：它們是理想的多元化方式嗎？</li>
<li>Visa 超過第三季度盈利預期，市場為何恐慌？</li>
<li>英國市場假期有哪些？如何投資和交易</li>
<li>Marvell 如何從短期目標變成突破明星</li>
<li>寶潔 NYSE: PG 在不穩定的指引後回落</li>
<li>Palo Alto Networks：全能網絡安全巨頭</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1FRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Amedisys Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Amedisys 嗎？</h2>
</div><p>Before you consider Amedisys, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Amedisys 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Amedisys 並不在名單上。</p>
</div><p>While Amedisys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Amedisys 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Wealthquest 公司在阿米斯醫療公司（納斯達克股票代碼：AMED）中建立了持倉